JP2022537269A5 - - Google Patents

Info

Publication number
JP2022537269A5
JP2022537269A5 JP2021573213A JP2021573213A JP2022537269A5 JP 2022537269 A5 JP2022537269 A5 JP 2022537269A5 JP 2021573213 A JP2021573213 A JP 2021573213A JP 2021573213 A JP2021573213 A JP 2021573213A JP 2022537269 A5 JP2022537269 A5 JP 2022537269A5
Authority
JP
Japan
Prior art keywords
antigen
muc16
cancer
agonist
combination according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021573213A
Other languages
English (en)
Japanese (ja)
Other versions
JP7743314B2 (ja
JP2022537269A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/038669 external-priority patent/WO2020257604A1/en
Publication of JP2022537269A publication Critical patent/JP2022537269A/ja
Publication of JP2022537269A5 publication Critical patent/JP2022537269A5/ja
Priority to JP2024144172A priority Critical patent/JP2024164188A/ja
Application granted granted Critical
Publication of JP7743314B2 publication Critical patent/JP7743314B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021573213A 2019-06-21 2020-06-19 Muc16およびcd3に結合する二重特異性抗原結合分子の4-1bb共刺激と組み合わせての使用 Active JP7743314B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024144172A JP2024164188A (ja) 2019-06-21 2024-08-26 Muc16およびcd3に結合する二重特異性抗原結合分子の4-1bb共刺激と組み合わせての使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962864960P 2019-06-21 2019-06-21
US62/864,960 2019-06-21
PCT/US2020/038669 WO2020257604A1 (en) 2019-06-21 2020-06-19 Use of bispecific antigen-binding molecules that bind muc16 and cd3 in combination with 4-1bb co-stimulation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024144172A Division JP2024164188A (ja) 2019-06-21 2024-08-26 Muc16およびcd3に結合する二重特異性抗原結合分子の4-1bb共刺激と組み合わせての使用

Publications (3)

Publication Number Publication Date
JP2022537269A JP2022537269A (ja) 2022-08-25
JP2022537269A5 true JP2022537269A5 (cg-RX-API-DMAC10.html) 2023-06-20
JP7743314B2 JP7743314B2 (ja) 2025-09-24

Family

ID=71842848

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021573213A Active JP7743314B2 (ja) 2019-06-21 2020-06-19 Muc16およびcd3に結合する二重特異性抗原結合分子の4-1bb共刺激と組み合わせての使用
JP2024144172A Pending JP2024164188A (ja) 2019-06-21 2024-08-26 Muc16およびcd3に結合する二重特異性抗原結合分子の4-1bb共刺激と組み合わせての使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024144172A Pending JP2024164188A (ja) 2019-06-21 2024-08-26 Muc16およびcd3に結合する二重特異性抗原結合分子の4-1bb共刺激と組み合わせての使用

Country Status (12)

Country Link
US (2) US12091460B2 (cg-RX-API-DMAC10.html)
EP (1) EP3986934A1 (cg-RX-API-DMAC10.html)
JP (2) JP7743314B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220024035A (cg-RX-API-DMAC10.html)
CN (2) CN118453851A (cg-RX-API-DMAC10.html)
AU (1) AU2020294790A1 (cg-RX-API-DMAC10.html)
CA (1) CA3140083A1 (cg-RX-API-DMAC10.html)
IL (2) IL288916B2 (cg-RX-API-DMAC10.html)
MA (1) MA56537A (cg-RX-API-DMAC10.html)
MX (1) MX2021015270A (cg-RX-API-DMAC10.html)
WO (1) WO2020257604A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202108895B (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102531251B1 (ko) * 2016-09-23 2023-05-15 리제너론 파아마슈티컬스, 인크. 이특이적 항-muc16-cd3 항체 및 항-muc16 약물 접합체
EP4308160A4 (en) * 2021-03-18 2025-07-02 Memorial Sloan Kettering Cancer Center METHODS OF TREATING GYNECOLOGICAL CANCER USING COMBINATION THERAPY WITH MULTISPECIFIC ANTI-MUC16 X CD3 ANTIBODIES AND VEGF INHIBITORS
IL315405A (en) * 2022-03-17 2024-11-01 Regeneron Pharma Methods for treating recurrent epithelioid sarcoma using bispecific anti-MUC16 and anti-CD3 antibodies alone or in combination with anti-PD-1 antibodies
JP2025529310A (ja) * 2022-09-06 2025-09-04 ティージェイ バイオファーマ (シャンハイ) カンパニー, リミテッド 多特異性構築物およびその使用
WO2025082777A1 (en) * 2023-10-17 2025-04-24 Morphosys Ag Dual-targeting of muc16 and mesothelin co-expressing tumor cells by functional complementation of cycat® halfbody molecules
TW202542187A (zh) * 2023-12-12 2025-11-01 美商再生元醫藥公司 以雙特異性抗muc16x抗cd3抗體單獨或與抗pd-1抗體組合治療子宮內膜癌之方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5428156A (en) 1993-04-02 1995-06-27 Associated Universities, Inc. Synthesis of macrocyclic polyaminocarboxylates and their use for preparing stable radiometal antibody immunoconjugates for therapy, spect and pet imaging
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
WO2008119567A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
SG183149A1 (en) 2010-02-08 2012-09-27 Regeneron Pharma Common light chain mouse
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗pd-l1之人類抗體
US11033642B2 (en) 2014-03-19 2021-06-15 Universitat Zurich Multidentate bifunctional chelating agents for radionuclide complexation in diagnostics and therapy
CA2949936C (en) * 2014-06-10 2022-10-18 3B Pharmaceuticals Gmbh Conjugate comprising a neurotensin receptor ligand and use thereof
NZ731966A (en) * 2014-10-16 2019-11-29 Univ Melbourne Novel imaging composition and uses thereof
KR102618312B1 (ko) 2015-03-17 2023-12-28 메모리얼 슬로안 케터링 캔서 센터 항muc16 항체 및 그의 용도
JOP20160154B1 (ar) 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
MY195059A (en) * 2015-09-23 2023-01-05 Regeneron Pharma Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof
KR102531251B1 (ko) * 2016-09-23 2023-05-15 리제너론 파아마슈티컬스, 인크. 이특이적 항-muc16-cd3 항체 및 항-muc16 약물 접합체
RS67792B1 (sr) * 2016-12-01 2026-03-31 Regeneron Pharma Radio-obeležena anti-pd-l1 antitela za imuno-pet snimanje
JP7125400B2 (ja) 2016-12-19 2022-08-24 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 標的化4-1bb(cd137)アゴニストとの併用療法
KR102692708B1 (ko) * 2016-12-20 2024-08-07 에프. 호프만-라 로슈 아게 항-cd20/항-cd3 이중특이성 항체 및 4-1bb(cd137) 작용물질의 병용 요법

Similar Documents

Publication Publication Date Title
JP2021166522A (ja) キメラ抗原受容体組成物
JP2022017295A (ja) Hdac阻害剤とpd-l1阻害剤との組み合わせ療法
TWI549690B (zh) 包含抗-cd19類美登素(maytansinoid)免疫結合物及利妥昔單抗(rituximab)之用於治療cd19+b-細胞惡性症狀之組合療法
JP2022537019A5 (cg-RX-API-DMAC10.html)
JP2021519076A5 (cg-RX-API-DMAC10.html)
TW200813090A (en) Combinatorial therapy
TWI641385B (zh) 抗腫瘤劑及抗腫瘤效果增強劑
WO2009147695A1 (ja) 抗がん剤
JP2021523100A5 (cg-RX-API-DMAC10.html)
JP2022527081A (ja) 血液がんおよび固形がんの治療のためのキメラ抗原受容体改変t細胞(car-t)
AU2020228296B2 (en) Administration of PD-1 inhibitors for treating skin cancer
JP7374765B2 (ja) 抗dkk-1抗体を使用して癌を治療するためのバイオマーカーとしてのベータ-カテニンの使用
JP2024546605A5 (cg-RX-API-DMAC10.html)
JP2022543765A5 (cg-RX-API-DMAC10.html)
JPWO2016104657A1 (ja) 癌治療剤
TW202330040A (zh) 抗her2抗體藥物偶聯物和酪胺酸激酶抑制劑聯合在製備治療腫瘤的藥物中的用途
JP2025515092A5 (cg-RX-API-DMAC10.html)
WO2022233262A1 (zh) 抗体药物偶联物治疗癌症的方法及用途
JP2025501978A5 (cg-RX-API-DMAC10.html)
WO2019214492A1 (zh) 抗her2抗体-药物偶联物在治疗癌症中的用途
JP2022517415A5 (cg-RX-API-DMAC10.html)
JP2003520250A (ja) 一部の癌の治療における抗フェリチンモノクローナル抗体の使用
WO2021057764A1 (zh) Pd-1抗体联合紫杉类化合物在制备治疗三阴性乳腺癌的药物中的用途
US20240100053A1 (en) Pharmaceutical composition
JP2025515205A5 (cg-RX-API-DMAC10.html)